|
|
 | | | |
- close
- close
- close
- close
| |||||||||
ELN » Topics » We are subject to pricing pressures and uncertainties regarding healthcare reimbursement and reform.This excerpt taken from the ELN 6-K filed Mar 30, 2009. We
are subject to pricing pressures and uncertainties regarding
healthcare reimbursement and reform.
In the United States, many pharmaceutical products and biologics
are subject to increasing pricing pressures. Our ability to
commercialise products successfully depends, in part, upon the
extent to which healthcare providers are reimbursed by
third-party payers, such as governmental agencies, including the
Centers for Medicare and Medicaid Services, private health
insurers and other organisations, such as health maintenance
organisations (HMOs), for the cost of such products and related
treatments. In addition, if healthcare providers do not view
current or future Medicare reimbursements for our products
favourably, then they may not prescribe our products.
Third-party payers are increasingly challenging the pricing of
pharmaceutical products by, among other things, limiting the
pharmaceutical products that are on their formulary lists. As a
result, competition among pharmaceutical companies to place
their products on these formulary lists has reduced product
prices. If reasonable reimbursement for our products is
unavailable or if significant downward pricing pressures in the
industry occur, then we could be materially and adversely
affected.
The new administration and Congress in the United States have
made significant healthcare reform a priority. Any fundamental
healthcare reform may change the manner by which drugs and
biologics are developed, marketed and purchased. In addition,
managed care organisations, HMOs, preferred provider
organisations, institutions and other government agencies
continue to seek price discounts. Further, certain states have
proposed and certain other states have adopted various
programmes to control prices for their seniors’ and
low-income drug programmes, including price or patient
reimbursement constraints, restrictions on access to certain
products, importation from other countries, such as Canada, and
bulk purchasing of drugs.
Table of Contents
Risk Factors
We encounter similar regulatory and legislative issues in most
other countries. In the European Union and some other
international markets, the government provides healthcare at low
direct cost to consumers and regulates pharmaceutical prices or
patient reimbursement levels to control costs for the
government-sponsored healthcare system. This price regulation
leads to inconsistent prices and some third-party trade in our
products from markets with lower prices. Such trade-exploiting
price differences between countries could undermine our sales in
markets with higher prices.
This excerpt taken from the ELN 20-F filed Feb 26, 2009. We are
subject to pricing pressures and uncertainties regarding
healthcare reimbursement and reform.
In the United States, many pharmaceutical products and biologics
are subject to increasing pricing pressures. Our ability to
commercialize products successfully depends, in part, upon the
extent to which healthcare providers are reimbursed by
third-party payers, such as governmental agencies, including the
Centers for Medicare and Medicaid Services, private health
insurers and other organizations, such as health maintenance
organizations (HMOs), for the cost of such products and related
treatments. In addition, if healthcare providers do not view
current or future Medicare reimbursements for our products
favorably, then they may not prescribe our products. Third-party
payers are increasingly challenging the pricing of
pharmaceutical products by, among other things, limiting the
pharmaceutical products that are on their formulary lists. As a
result, competition among pharmaceutical companies to place
their products on these formulary lists has reduced product
prices. If reasonable reimbursement for our products is
unavailable or if significant downward pricing pressures in the
industry occur, then we could be materially and adversely
affected.
The new administration and Congress in the United States have
made significant healthcare reform a priority. Any fundamental
healthcare reform may change the manner by which drugs and
biologics are developed, marketed and purchased. In addition,
managed care organizations, HMOs, preferred provider
organizations, institutions and other government agencies
continue to seek price discounts. Further, certain states have
proposed and certain other states have adopted various programs
to control prices for their seniors’ and low-income drug
programs, including price or patient reimbursement constraints,
restrictions on access to certain products, importation from
other countries, such as Canada, and bulk purchasing of drugs.
We encounter similar regulatory and legislative issues in most
other countries. In the European Union and some other
international markets, the government provides health care at
low direct cost to consumers and regulates pharmaceutical prices
or patient reimbursement levels to control costs for the
government-sponsored healthcare system. This price regulation
leads to inconsistent prices and some third-party trade in our
products from markets with lower prices. Such trade-exploiting
price differences between countries could undermine our sales in
markets with higher prices.
This excerpt taken from the ELN 6-K filed Mar 31, 2008. We
are subject to pricing pressures and uncertainties regarding
healthcare reimbursement and reform.
In the United States, many pharmaceutical products and biologics
are subject to increasing pricing pressures, including pressures
arising from recent Medicare reform. Our ability to
commercialise products successfully depends, in part, upon the
extent to which healthcare providers are reimbursed by
third-party payers, such as governmental agencies, including the
Centers for Medicare and Medicaid Services, private health
insurers and other organisations, such as health maintenance
organisations (HMOs), for the cost of such products and related
treatments. In addition, if healthcare providers do not view
current or future Medicare reimbursements for our products
favourably, then they may not prescribe our products.
Third-party payers are increasingly challenging the pricing of
pharmaceutical products by, among other things, limiting the
pharmaceutical products that are on their formulary lists. As a
result, competition among pharmaceutical companies to place
their products on these formulary lists has reduced product
prices. If reasonable reimbursement for our products is
unavailable or if significant downward pricing pressures in the
industry occur, then we could be materially adversely affected.
Elan Corporation, plc 2007 Annual
Report 147
Table of Contents
Recent reforms in Medicare added a prescription drug
reimbursement benefit for all Medicare beneficiaries. Although
we cannot predict the full effects on our business of this
legislation, it is possible that the new benefit, which is being
managed by private health insurers, pharmacy benefit managers,
and other managed care organisations, will result in decreased
reimbursement for prescription drugs, which may further
exacerbate industry-wide pressure to reduce the prices charged
for prescription drugs. This could harm our ability to generate
revenues. In addition, managed care organisations, HMOs,
preferred provider organisations, institutions and other
government agencies continue to seek price discounts. In
addition, certain states have proposed and certain other states
have adopted various programmes to control prices for their
seniors’ and low-income drug programmes, including price or
patient reimbursement constraints, restrictions on access to
certain products, importation from other countries, such as
Canada, and bulk purchasing of drugs.
We encounter similar regulatory and legislative issues in most
other countries. In the European Union and some other
international markets, the government provides health care at
low direct cost to consumers and regulates pharmaceutical prices
or patient reimbursement levels to control costs for the
government-sponsored healthcare system. This price regulation
leads to inconsistent prices and some third-party trade in our
products from markets with lower prices. Such trade-exploiting
price differences between countries could undermine our sales in
markets with higher prices.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. We are
subject to pricing pressures and uncertainties regarding
healthcare reimbursement and reform.
In the United States, many pharmaceutical products and biologics
are subject to increasing pricing pressures, including pressures
arising from recent Medicare reform. Our ability to
commercialize products successfully depends, in part, upon the
extent to which healthcare providers are reimbursed by
third-party payers, such as governmental agencies, including the
Centers for Medicare and Medicaid Services, private health
insurers and other organizations, such as health maintenance
organizations (HMOs), for the cost of such products and related
treatments. In addition, if healthcare providers do not view
current or future Medicare reimbursements for our products
favorably, then they may not prescribe our products. Third-party
payers are increasingly challenging the pricing of
pharmaceutical products by, among other things, limiting the
pharmaceutical products that are on their formulary lists. As a
result, competition among pharmaceutical companies to place
their products on these formulary lists has reduced product
prices. If reasonable reimbursement for our products is
unavailable or if significant downward pricing pressures in the
industry occur, then we could be materially adversely affected.
Recent reforms in Medicare added a prescription drug
reimbursement benefit for all Medicare beneficiaries. Although
we cannot predict the full effects on our business of this
legislation, it is possible that the new benefit, which is being
managed by private health insurers, pharmacy benefit managers,
and other managed care organizations, will result in decreased
reimbursement for prescription drugs, which may further
exacerbate industry-wide pressure to reduce the prices charged
for prescription drugs. This could harm our ability to generate
revenues. In addition, managed care organizations, HMOs,
preferred provider organizations, institutions and other
government agencies continue to seek price discounts. In
addition, certain states have proposed and certain other states
have adopted various programs to control prices for their
seniors’ and low-income drug programs, including price or
patient reimbursement constraints, restrictions on access to
certain products, importation from other countries, such as
Canada, and bulk purchasing of drugs.
We encounter similar regulatory and legislative issues in most
other countries. In the European Union (EU) and some other
international markets, the government provides health care at
low direct cost to consumers and regulates pharmaceutical prices
or patient reimbursement levels to control costs for the
government-sponsored healthcare system. This price regulation
leads to inconsistent prices and some third-party trade in our
products from markets with lower prices. Such trade-exploiting
price differences between countries could undermine our sales in
markets with higher prices.
This excerpt taken from the ELN 6-K filed Mar 30, 2007. We
are subject to pricing pressures and uncertainties regarding
healthcare reimbursement and reform.
In the United States, many pharmaceutical products and biologics
are subject to increasing pricing pressures, including pressures
arising from recent Medicare reform. Our ability to
commercialise products successfully depends, in part, upon the
extent to which health care providers are reimbursed by
third-party payers, such as governmental agencies, including the
Centers for Medicare and Medicaid Services, private health
insurers and other organisations, such as health maintenance
organisations (HMOs), for the cost of such products and related
treatments. In addition, if health care providers do not view
current or future Medicare reimbursements for our products
favourably, then they may not prescribe our products.
Third-party payers are increasingly challenging the pricing of
pharmaceutical products by, among other things, limiting the
pharmaceutical products that are on their formulary lists. As a
result, competition among pharmaceutical companies to place
their products on these formulary
146 Elan
Corporation, plc 2006 Annual Report
Table of Contents
Risk Factors
lists has reduced product prices. If reasonable reimbursement
for our products is unavailable or if significant downward
pricing pressures in the industry occur, then we could be
materially adversely affected.
Recent reforms in Medicare added a prescription drug
reimbursement benefit for all Medicare beneficiaries. Although
we cannot predict the full effects on our business of this
legislation, it is possible that the new benefit, which is being
managed by private health insurers, pharmacy benefit managers,
and other managed care organisations, will result in decreased
reimbursement for prescription drugs, which may further
exacerbate industry-wide pressure to reduce the prices charged
for prescription drugs. This could harm our ability to generate
revenues. In addition, Managed Care Organizations, HMOs,
Preferred Provider Organizations, institutions and other
government agencies continue to seek price discounts. In
addition, certain states have proposed and certain other states
have adopted various programmes to control prices for their
seniors’ and low-income drug programmes, including price or
patient reimbursement constraints, restrictions on access to
certain products, importation from other countries, such as
Canada, and bulk purchasing of drugs.
We encounter similar regulatory and legislative issues in most
other countries. In the European Union and some other
international markets, the government provides health care at
low direct cost to consumers and regulates pharmaceutical prices
or patient reimbursement levels to control costs for the
government-sponsored health care system. This price regulation
may lead to inconsistent prices and some third-party trade in
our products from markets with lower prices. Such trade
exploiting price differences between countries could undermine
our sales in markets with higher prices.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. We are
subject to pricing pressures and uncertainties regarding
healthcare reimbursement and reform.
In the United States, many pharmaceutical products and biologics
are subject to increasing pricing pressures, including pressures
arising from recent Medicare reform. Our ability to
commercialize products successfully depends, in part, upon the
extent to which health care providers are reimbursed by
third-party payers, such as governmental agencies, including the
Centers for Medicare and Medicaid Services, private health
insurers and other organizations, such as health maintenance
organizations (HMOs), for the cost of such products and related
treatments. In addition, if health care providers do not view
current or future Medicare reimbursements for our products
favorably, then they may not prescribe our products. Third-party
payers are increasingly challenging the pricing of
pharmaceutical products by, among other things, limiting the
pharmaceutical products that are on their formulary lists. As a
result, competition among pharmaceutical companies to place
their products on these formulary lists has reduced product
prices. If reasonable reimbursement for our products is
unavailable or if significant downward pricing pressures in the
industry occur, then we could be materially adversely affected.
Recent reforms in Medicare added a prescription drug
reimbursement benefit for all Medicare beneficiaries. Although
we cannot predict the full effects on our business of this
legislation, it is possible that the new benefit, which is being
managed by private health insurers, pharmacy benefit managers,
and other managed care organizations, will result in decreased
reimbursement for prescription drugs, which may further
exacerbate industry-wide pressure to reduce the prices charged
for prescription drugs. This could harm our ability to generate
revenues. In addition, Managed Care Organizations, HMOs,
Preferred Provider Organizations, institutions and other
government agencies continue to seek price discounts. In
addition, certain states have proposed and certain other states
have adopted various programs to control prices for their
seniors’ and low-income drug programs, including price or
patient reimbursement constraints, restrictions on access to
certain products, importation from other countries, such as
Canada, and bulk purchasing of drugs.
We encounter similar regulatory and legislative issues in most
other countries. In the European Union (EU) and some other
international markets, the government provides health care at
low direct cost to consumers and regulates pharmaceutical prices
or patient reimbursement levels to control costs for the
government-sponsored health care system. This price regulation
may lead to inconsistent prices and some third-party trade in
our products from
Table of Contents
markets with lower prices. Such trade exploiting price
differences between countries could undermine our sales in
markets with higher prices.
This excerpt taken from the ELN 6-K filed Mar 31, 2006. We are subject to pricing pressures
and uncertainties regarding healthcare reimbursement and
reform.
In the United States, many pharmaceutical products and biologics
are subject to increasing pricing pressures, including pressures
arising from recent Medicare reform. Our ability to
commercialise products successfully depends, in part, upon the
extent to which health care providers are reimbursed by
third-party payers, such as governmental agencies, including the
Centers for Medicare and Medicaid Services, private health
insurers and other organisations, such as health maintenance
organisations (HMOs), for the cost of such products and related
treatments. In addition, if health care providers do not view
current or future Medicare reimbursements for our products
favourably, then they may not prescribe our products.
Third-party payers are increasingly challenging the pricing of
pharmaceutical products by, among other things, limiting the
pharmaceutical products that are on their formulary lists. As a
result, competition among pharmaceutical companies to place
their products on these formulary lists has reduced product
prices. If reasonable reimbursement for our products is
unavailable or if significant downward pricing pressures in the
industry occur, then we could be materially adversely affected.
Recent reforms in Medicare added a prescription drug
reimbursement benefit beginning in 2006 for all Medicare
beneficiaries. Although we cannot predict the full effects on
our business of the implementation of this legislation, it is
possible that the new benefit, which will be managed by private
health insurers, pharmacy benefit managers, and other managed
care organisations, will result in decreased reimbursement for
prescription drugs, which may further exacerbate industry-wide
pressure to reduce the prices charged for prescription drugs.
This could harm our ability to generate revenues. In addition,
Managed Care Organizations, HMOs, Preferred Provider
Organizations, institutions and other government agencies
continue to seek price discounts. In addition, certain states
have proposed and certain other states have adopted various
programmes to control prices for their seniors’ and
low-income drug programmes, including price or patient
reimbursement constraints, restrictions on access to certain
products, importation from other countries, such as Canada, and
bulk purchasing of drugs.
We encounter similar regulatory and legislative issues in most
other countries. In the EU and some other international markets,
the government provides health care at low direct cost to
consumers and regulates pharmaceutical prices or patient
reimbursement levels to control costs for the
government-sponsored health care system. This price regulation
may lead to inconsistent prices and some third-party trade in
our products from markets with lower prices. Such trade
exploiting price differences between countries could undermine
our sales in markets with higher prices.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. We are
subject to pricing pressures and uncertainties regarding
healthcare reimbursement and reform.
In the United States, many pharmaceutical products and biologics
are subject to increasing pricing pressures, including pressures
arising from recent Medicare reform. Our ability to
commercialize products successfully depends, in part, upon the
extent to which health care providers are reimbursed by
third-party payers, such as governmental agencies, including the
Centers for Medicare and Medicaid Services, private health
insurers and other organizations, such as health maintenance
organizations (HMOs), for the cost of such products and related
treatments. In addition, if health care providers do not view
current or future Medicare reimbursements for our products
favorably, then they may not prescribe our products. Third-party
payers are increasingly challenging the pricing of
pharmaceutical products by, among other things, limiting the
pharmaceutical products that are on their formulary lists. As a
result, competition among pharmaceutical companies to place
their products on these formulary lists has reduced product
prices. If reasonable reimbursement for our products is
unavailable or if significant downward pricing pressures in the
industry occur, then we could be materially adversely affected.
Recent reforms in Medicare added a prescription drug
reimbursement benefit beginning in 2006 for all Medicare
beneficiaries. Although we cannot predict the full effects on
our business of the implementation of this legislation, it is
possible that the new benefit, which will be managed by private
health insurers, pharmacy benefit managers, and other managed
care organizations, will result in decreased reimbursement for
prescription drugs, which may further exacerbate industry-wide
pressure to reduce the prices charged for prescription drugs.
This could harm our ability to generate revenues. In addition,
Managed Care Organizations, HMOs, Preferred Provider
Organizations, institutions and other government agencies
continue to seek price discounts. In addition, certain states
have proposed and certain other states have adopted various
programs to control prices for their seniors’ and
low-income drug programs, including price or patient
reimbursement constraints, restrictions on access to certain
products, importation from other countries, such as Canada, and
bulk purchasing of drugs.
We encounter similar regulatory and legislative issues in most
other countries. In the European Union (EU) and some other
international markets, the government provides health care at
low direct cost to consumers and regulates pharmaceutical prices
or patient reimbursement levels to control costs for the
government-sponsored health care system. This price regulation
may lead to inconsistent prices and some third-party trade in
our products from markets with lower prices. Such trade
exploiting price differences between countries could undermine
our sales in markets with higher prices.
This excerpt taken from the ELN 6-K filed Apr 11, 2005. We are subject to pricing pressures and uncertainties regarding healthcare reimbursement and reform. In the U.S., many pharmaceutical products and biologics are subject to increasing pricing pressures, including pressures arising from recent Medicare reform. Our ability to commercialise products successfully depends, in part, upon the extent to which health care providers are reimbursed by third party payors, such as governmental agencies, including the Centers for Medicare and Medicaid Services, private health insurers and other organisations, such as HMOs, for the cost of such products and related treatments. In addition, if health care providers do not view current or future Medicare reimbursements for our products favourably, then they may not prescribe our products. Third-party payers are increasingly challenging the pricing of pharmaceutical products by, among other things, limiting the pharmaceutical products that are on their formulary lists. As a result, competition among pharmaceutical companies to place their products on these formulary lists has reduced product prices. If reasonable reimbursement for our products is unavailable or if significant downward pricing pressures in the industry occur, then we could be materially adversely affected. Recent reforms in Medicare added a prescription drug reimbursement benefit beginning in 2006 for all Medicare beneficiaries. In the meantime, a temporary drug discount card program was established for Medicare beneficiaries. Although we cannot predict the full effects on our business of the implementation of this legislation, it is possible that the new benefit, which will be managed by private health insurers, pharmacy benefit managers, and other managed care
organisations, will result in decreased reimbursement for prescription drugs, which may further exacerbate industry-wide pressure to reduce the prices charged for prescription drugs. This could harm our ability to generate revenues. In addition, Managed Care Organizations, HMOs, Preferred Provider Organizations, institutions and other government agencies continue to seek price discounts. In addition, certain states have proposed and certain other states have adopted various programmes to control prices for their seniors’ and low-income drug programmes, including price or patient reimbursement constraints, restrictions on access to certain products, importation from other countries, such as Canada, and bulk purchasing of drugs. We encounter similar regulatory and legislative issues in most other countries. In the EU and some other international markets, the government provides health care at low direct cost to consumers and regulates pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored health care system. This price regulation may lead to inconsistent prices and some third-party trade in our products from markets with lower prices. Such trade exploiting price differences between countries could undermine our sales in markets with higher prices. | EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN:
|
| |||||||
